An IL28B genotype-based clinical prediction model for treatment of Chronic Hepatitis C

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  O'Brien, Thomas R ^a   Everhart, James E ^b   Morgan, Timothy R ^c,d   Lok, Anna S ^e   Chung, Raymond T ^f   Shao, Yongwu ^g   Shiffman, Mitchell L ^h   Dotrang, Myhanh ⁱ   Sninsky, John J ^j   Bonkovsky, Herbert L ^k,l   Pfeiffer, Ruth M ^a   the HALT C Trial Group, ^m  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g INFORMATION MANAGEMENT SERVICES INC   (United States)

^h Bon Secours Health System   (United States)

ⁱ CSC   (United States)

^j CELERA   (United States)

^k UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^l CAROLINAS MEDICAL CENTER   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; AREA UNDER THE CURVE; BIOLOGICAL MODEL; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECT; GENETICS; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; AREA UNDER CURVE; DEMOGRAPHY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79960081869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020904     Document Type: Article

References (27)

1. (2002) NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 19: 1-46.
2. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
3. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
4. Bowden DS, Berzsenyi MD, (2006) Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiology 1: 103-112.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
6. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B Is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345.
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
9. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
10. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, et al. (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
11. Robek MD, Boyd BS, Chisari FV, (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79: 3851-3854.
12. O'Brien TR, (2009) Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 41: 1048-1050.
13. Siren J, Pirhonen J, Julkunen I, Matikainen S, (2005) IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 174: 1932-1937.
14. Feero WG, Guttmacher AE, Collins FS, (2010) Genomic medicine - An updated primer. N Engl J Med 362: 2001-2011.
15. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, et al. (2004) Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25: 472-492.
16. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429-2441.
17. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, et al. (2006) HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 44: 360-367.
18. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, et al. (2009) Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49: 1847-1858.
19. Germer S, Holland MJ, Higuchi R, (2000) High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10: 258-266.
20. Molinaro AM, Simon R, Pfeiffer RM, (2005) Prediction error estimation: a comparison of resampling methods. Bioinformatics 21: 3301-3307.
21. Pepe MS, (2003) The statistical evaluation of medical tests for classification and prediction Oxford Oxford University Press.
22. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 139: 120-129.
23. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292-1303.
24. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, et al. (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360: 1839-1850.
25. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827-1838.
26. Sarrazin C, Zeuzem S, (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138: 447-462.
27. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, et al. (2010) Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52: 421-429.